Correvio Pharma Corp

Correvio Pharma — Q3 2019 Earnings Presentation

14 slides from Correvio Pharma's earnings presentation, Nov 14, 2019

  1. Slide 1: Third Quarter 2019 Financial Results Conference Call

    Third Quarter 2019 Financial Results Conference Call November 14, 2019 NASDAQ: CORV / TSX: CORV

  2. Slide 2: Forward Looking Statement Disclaimer

    Forward Looking Statement Disclaimer ● Certain statements in this presentation contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” under applicable Canadian securities legislation (collectively, "forwar

  3. Slide 3: Executing on Final Regulatory Steps

    Executing on Final Regulatory Steps ● Following Type C meeting with FDA Correvio resubmitted Brinavess NDA in Q2 2019 ● Resubmission accepted by FDA in July 2019 ● FDA Advisory Committee scheduled for Dec 10, 2019 ● PDUFA target action date of December 24, 2019 ● Eligible to apply for formal patent

  4. Slide 4: A Strong Body of Real-World Data

    A Strong Body of Real-World Data SPECTRUM 34 ISTs and Other Post- 59K Approval Studies ● Post authorization safety study (EU) ● Brinavess has been the subject of ● Over 8 years of real-world ● 1,778 unique patients with 2,009 treatment experience from over 59,000 episodes at 53 centers in 6 countrie

  5. Slide 5: Expanding Physician Awareness

    Expanding Physician Awareness ACC 2020 JACC AHA 2019 Planning for a strong Manuscript submitted presence at the Presented Post hoc analysis of to a prestigious U.S. upcoming American SPECTRUM data SPECTRUM patients medical journal for College of Cardiology at the upcoming specifically treated in the

  6. Slide 6: New SPECTRUM Data to be Presented at AHA 2019

    SPECTRUM at AHA 2019 New SPECTRUM Data to be Presented at AHA 2019 ● New post hoc analysis data ● 1,289 unique patients treated specifically in the ER ● 70.2% efficacy with 12-minute median time to conversion ● Median length of hospital stay was 7.5 hours; only 13% of patients were in hospital for >

  7. Slide 7: U.S. Market Opportunity – Key Research Findings

    U.S. Market Opportunity – Key Research Findings 7.1M >500K 10 years >$1B Prevalence of Atrial Cardioversions First New Treatment $1B Addressable Fibrillation Performed in 10 Years Market Growing to $1.9B by 2030 7.1 million unique According to actual claims If approved, Brinavess will Independent re

  8. Slide 8: EU Marketed Products and Major Regulatory Decisions Upcoming

    4 EU Marketed Products and 2 Major Regulatory Decisions Upcoming $21.3M in YTD revenue through September 30, 2019; +8% vs same period in 2018 Product Brand Therapeutic Area Partner / Innovator Product Positioning • 60+ countries Cardiovascular via Correvio • Limited/no promotion (genericized) • Nord

  9. Slide 9: United Therapeutics Trevyent Update

    United Therapeutics Trevyent® Update ✓ FDA has accepted United Therapeutics’ (NASDAQ: UTHR) Trevyent NDA ✓ Assigned a PDUFA date of April 27, 2020 ▪ Correvio plans to submit a regulatory filing for TREVYENT in Europe in second half of 2020 “[Trevyent] is going to be “…truly a plug-and-play system.”

  10. Slide 10: Positive Sales Trends for Anti-Infective Franchise

    Positive Sales Trends for Anti-Infective Franchise Quarterly Sales Evolution 3,000 2,500 Zevtera /Mabelio 18% (ceftobiprole medocaril sodium) 2,000 1,500 1,000 500 0 2018 Q1 2018 Q2 2018 Q3 2018 Q4 2019 Q1 2019 Q2 2019 Q3 10 | CORREVIO PRESENTATION | NASDAQ: CORV | TSX: CORV | WWW.CORREVIO.COM | 201

  11. Slide 11: Q3 2019 Financials

    Q3 2019 Financials Q3 2019 Highlights Quarter ended $ in thousands September 30, 2019 September 30, 2018 ● On track to deliver FY Revenue $ 6,669 $ 7,007 2019 revenues that are Gross Profit 4,395 4,872 Expenses 20% above FY 2018 Selling, general and administration (11,186) (9,186) Amortization and d

  12. Slide 12: Progress and Brinavess Milestones

    Progress and Brinavess Milestones 2019 2020 Q2 Q3 Q4 Q1 Q2 2019: Q3 2019: Q3 2019: Q4 2019: Q4 2019: Q4 2019: H1 2020: NDA NDA ESC 2019 Regulatory FDA PDUFA/ Potential re-submission acceptance SPECTRUM data clarity from Advisory FDA US to FDA presented at the China FDA Committee decision partnership

  13. Slide 13: Question & Answer Session

    Question & Answer Session NASDAQ: CORV / TSX: CORV

  14. Slide 14: Thank You!

    Thank You! Investor Contacts Brendan Payne Argot Partners Assoc. Dir., Investor Relations Michelle Carroll/Claudia Styslinger and Business Development 212.600.1902 Correvio Pharma Corp. michelle@argotpartners.com 604.677.6905 ext. 306 claudia@argotpartners.com 800.330.9928 bpayne@correvio.com NASDAQ

Correvio Pharma — Q3 2019 Earnings Presentation on 6ix